391 related articles for article (PubMed ID: 33745032)
1. Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors.
Do KT; Manuszak C; Thrash E; Giobbie-Hurder A; Hu J; Kelland S; Powers A; de Jonge A; Shapiro GI; Severgnini M
Cancer Immunol Immunother; 2021 Oct; 70(10):2991-3000. PubMed ID: 33745032
[TBL] [Abstract][Full Text] [Related]
2. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Lee JM; Nair J; Zimmer A; Lipkowitz S; Annunziata CM; Merino MJ; Swisher EM; Harrell MI; Trepel JB; Lee MJ; Bagheri MH; Botesteanu DA; Steinberg SM; Minasian L; Ekwede I; Kohn EC
Lancet Oncol; 2018 Feb; 19(2):207-215. PubMed ID: 29361470
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors.
Do KT; Kochupurakkal B; Kelland S; de Jonge A; Hedglin J; Powers A; Quinn N; Gannon C; Vuong L; Parmar K; Lazaro JB; D'Andrea AD; Shapiro GI
Clin Cancer Res; 2021 Sep; 27(17):4710-4716. PubMed ID: 34131002
[TBL] [Abstract][Full Text] [Related]
4. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
Parmar K; Kochupurakkal BS; Lazaro JB; Wang ZC; Palakurthi S; Kirschmeier PT; Yang C; Sambel LA; Färkkilä A; Reznichenko E; Reavis HD; Dunn CE; Zou L; Do KT; Konstantinopoulos PA; Matulonis UA; Liu JF; D'Andrea AD; Shapiro GI
Clin Cancer Res; 2019 Oct; 25(20):6127-6140. PubMed ID: 31409614
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of prexasertib monotherapy in recurrent
Lampert EJ; Cimino-Mathews A; Lee JS; Nair J; Lee MJ; Yuno A; An D; Trepel JB; Ruppin E; Lee JM
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32709712
[TBL] [Abstract][Full Text] [Related]
6. Prexasertib: an investigational checkpoint kinase inhibitor for the treatment of high-grade serous ovarian cancer.
Evangelisti G; Barra F; Moioli M; Sala P; Stigliani S; Gustavino C; Costantini S; Ferrero S
Expert Opin Investig Drugs; 2020 Aug; 29(8):779-792. PubMed ID: 32539469
[TBL] [Abstract][Full Text] [Related]
7. Dose-finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors.
Iwasa S; Yamamoto N; Shitara K; Tamura K; Matsubara N; Tajimi M; Lin AB; Asou H; Cai Z; Inoue K; Shibasaki Y; Saito K; Takai H; Doi T
Cancer Sci; 2018 Oct; 109(10):3216-3223. PubMed ID: 30040168
[TBL] [Abstract][Full Text] [Related]
8. A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer.
Moore KN; Hong DS; Patel MR; Pant S; Ulahannan SV; Jones S; Meric-Bernstam F; Wang JS; Aljumaily R; Hamilton EP; Wittchen ES; Wang X; Lin AB; Bendell JC
Target Oncol; 2021 Sep; 16(5):569-589. PubMed ID: 34559360
[TBL] [Abstract][Full Text] [Related]
9. Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer.
Nair J; Huang TT; Murai J; Haynes B; Steeg PS; Pommier Y; Lee JM
Oncogene; 2020 Aug; 39(33):5520-5535. PubMed ID: 32647134
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.
Bendell JC; Bischoff HG; Hwang J; Reinhardt HC; Zander T; Wang X; Hynes S; Pitou C; Campbell R; Iversen P; Farrington DL; Bell-McGuinn K; Thomas M
Invest New Drugs; 2020 Aug; 38(4):1145-1155. PubMed ID: 31707688
[TBL] [Abstract][Full Text] [Related]
11. A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515).
Cash T; Fox E; Liu X; Minard CG; Reid JM; Scheck AC; Weigel BJ; Wetmore C
Pediatr Blood Cancer; 2021 Sep; 68(9):e29065. PubMed ID: 33881209
[TBL] [Abstract][Full Text] [Related]
12. A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast Cancer.
Gatti-Mays ME; Karzai FH; Soltani SN; Zimmer A; Green JE; Lee MJ; Trepel JB; Yuno A; Lipkowitz S; Nair J; McCoy A; Lee JM
Oncologist; 2020 Dec; 25(12):1013-e1824. PubMed ID: 32510664
[TBL] [Abstract][Full Text] [Related]
13. Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
Cho HY; Kim YB; Park WH; No JH
Cancer Res Treat; 2021 Jul; 53(3):819-828. PubMed ID: 33332934
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor.
Hong DS; Moore KN; Bendell JC; Karp DD; Wang JS; Ulahannan SV; Jones S; Wu W; Donoho GP; Ding Y; Capen A; Wang X; Bence Lin A; Patel MR
Clin Cancer Res; 2021 Apr; 27(7):1864-1874. PubMed ID: 33495309
[TBL] [Abstract][Full Text] [Related]
15. Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor-Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer.
Huang TT; Brill E; Nair JR; Zhang X; Wilson KM; Chen L; Thomas CJ; Lee JM
Cancer Res; 2020 Dec; 80(23):5380-5392. PubMed ID: 32998994
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.
Hong DS; Moore K; Patel M; Grant SC; Burris HA; William WN; Jones S; Meric-Bernstam F; Infante J; Golden L; Zhang W; Martinez R; Wijayawardana S; Beckmann R; Lin AB; Eng C; Bendell J
Clin Cancer Res; 2018 Jul; 24(14):3263-3272. PubMed ID: 29643063
[No Abstract] [Full Text] [Related]
17. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.
Konstantinopoulos PA; Cheng SC; Wahner Hendrickson AE; Penson RT; Schumer ST; Doyle LA; Lee EK; Kohn EC; Duska LR; Crispens MA; Olawaiye AB; Winer IS; Barroilhet LM; Fu S; McHale MT; Schilder RJ; Färkkilä A; Chowdhury D; Curtis J; Quinn RS; Bowes B; D'Andrea AD; Shapiro GI; Matulonis UA
Lancet Oncol; 2020 Jul; 21(7):957-968. PubMed ID: 32553118
[TBL] [Abstract][Full Text] [Related]
18. Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.
Lowery CD; Dowless M; Renschler M; Blosser W; VanWye AB; Stephens JR; Iversen PW; Lin AB; Beckmann RP; Krytska K; Cole KA; Maris JM; Hawkins DS; Rubin BP; Kurmasheva RT; Houghton PJ; Gorlick R; Kolb EA; Kang MH; Reynolds CP; Erickson SW; Teicher BA; Smith MA; Stancato LF
Clin Cancer Res; 2019 Apr; 25(7):2278-2289. PubMed ID: 30563935
[TBL] [Abstract][Full Text] [Related]
19. The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial.
Giudice E; Huang TT; Nair JR; Zurcher G; McCoy A; Nousome D; Radke MR; Swisher EM; Lipkowitz S; Ibanez K; Donohue D; Malys T; Lee MJ; Redd B; Levy E; Rastogi S; Sato N; Trepel JB; Lee JM
Nat Commun; 2024 Mar; 15(1):2805. PubMed ID: 38555285
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer.
Wan C; Keany MP; Dong H; Al-Alem LF; Pandya UM; Lazo S; Boehnke K; Lynch KN; Xu R; Zarrella DT; Gu S; Cejas P; Lim K; Long HW; Elias KM; Horowitz NS; Feltmate CM; Muto MG; Worley MJ; Berkowitz RS; Matulonis UA; Nucci MR; Crum CP; Rueda BR; Brown M; Liu XS; Hill SJ
Cancer Res; 2021 Jan; 81(1):158-173. PubMed ID: 33158814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]